XML 31 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814
Basis of Presentation and Summary of Significant Accounting Policies - Concentrations and Significant Customer Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Dec. 31, 2013
Investment Concentration Risk            
Cash, cash equivalents and investments $ 442,900   $ 442,900      
Investment in institutional money market funds 35,300   35,300      
Cash and cash equivalents 167,530 $ 196,154 167,530 $ 196,154 $ 119,296 $ 26,986
Amount invested in a single fund $ 34,300   $ 34,300      
Sales Revenue, Net | Customer Concentration Risk | Maximum            
Investment Concentration Risk            
Concentration risk (as a percent)     10.00%      
Sales Revenue, Net | Customer Concentration Risk | Amerisource Bergen Drug Corporation            
Investment Concentration Risk            
Concentration risk (as a percent) 28.00% 40.00% 25.00% 39.00%    
Sales Revenue, Net | Customer Concentration Risk | McKesson Corporation            
Investment Concentration Risk            
Concentration risk (as a percent) 13.00% 24.00% 11.00% 24.00%    
Sales Revenue, Net | Customer Concentration Risk | Cardinal Health Inc            
Investment Concentration Risk            
Concentration risk (as a percent) 7.00% 18.00% 5.00% 18.00%    
Sales Revenue, Net | Customer Concentration Risk | Takeda Pharmaceutical Company Limited            
Investment Concentration Risk            
Concentration risk (as a percent)   10.00% 17.00% 10.00%    
Sales Revenue, Net | Customer Concentration Risk | Group Purchasing Organization            
Investment Concentration Risk            
Concentration risk (as a percent)     25.00% 27.00%    
Sales Revenue, Net | Geographic Concentration Risk            
Investment Concentration Risk            
Approximate percentage of revenues from customers outside the U.S.     17.00% 11.00%    
Accounts Receivable | Credit Concentration Risk | Amerisource Bergen Drug Corporation            
Investment Concentration Risk            
Concentration risk (as a percent)     41.00%   45.00%  
Accounts Receivable | Credit Concentration Risk | McKesson Corporation            
Investment Concentration Risk            
Concentration risk (as a percent)     8.00%   12.00%